Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5811-5820 Newer>

CRM August 1, 2009 Lauren McKay	Healing the Sick Facing regulatory requirements, spiraling costs, and an aging (and ailing) customer base, the healthcare industry looks to CRM to balance a pair of age-old doctrines: First, do no harm - and physician, heal thyself.
CRM August 1, 2009 Christopher Musico	Patients Are Customers, Not Case Numbers "Healthcare" and "customer service" don't have to be mutually exclusive.
The Motley Fool August 3, 2009 Brian Orelli	The Roller-Coaster Stock That Keeps on Giving Savient's gout treatment isn't approved just yet.
Financial Planning August 1, 2009 Ilana Polyak	Critical Care As Congress wrestles with healthcare reform proposals under consideration, Kris Jenner, manager of the T. Rowe Price Health Sciences fund, is faced with just as difficult a task: how to make prudent investments in healthcare that can weather the seismic changes in the offing.
Chemistry World July 31, 2009 Matt Wilkinson	Agilent swoops on Varian Agilent is buying rival analytical instrument maker Varian for $1.5 billion ( 900 million) - a move that will increase its market share in the bioanalysis arena and mark its entry into the nuclear magnetic resonance (NMR) market.
Chemistry World July 31, 2009 Andy Extance	Pharma supplier accused of multi-million pound fraud The South African authorities are probing an alleged 1.2 billion fraud that used purchase orders claiming to be from leading drug firms to entice investors.
The Motley Fool July 31, 2009 Brian Orelli	Can Emerging Markets Save Pharma? Probably not until after they emerge.
The Motley Fool July 31, 2009 Brian Orelli	The Little Orphan That Could After a rough start to the year, Rule Breakers pick BioMarin Pharmaceutical is back on track.
The Motley Fool July 31, 2009 Brian Orelli	A Health-Care Investor's Nightmare When it comes to health-care reform, no news is not good news; the House's recent plan to delay voting on a health-care reform bill until September should have investors reaching for the antacids.
The Motley Fool July 31, 2009 Brian Orelli	Two Pictures of a Drug Company Who should we believe? The FDA? Mylan's earnings report?
<Older 5811-5820 Newer> Return to current articles.